Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

The sequencing of AML genomes of eight patients before and after relapse reveals two major patterns of clonal evolution, with chemotherapy appearing to have a role in both patterns. Many patients with acute myeloid leukaemia (AML) achieve remission, but it is often short-lived and the returned disease is usually refractory to therapy. Genome sequencing of eight patients with AML before and after relapse reveals two major patterns of tumour cell evolution. The founding clone survives chemotherapy in all patients, and, in one clonal pattern, it acquires new mutations and expands at relapse. In the other, a subclone surviving from the original tumour expands and then acquires new mutations. Comparisons of…

• FF
  Foundation for Barnes-Jewish Hospital

  Award: 00335-0505-02
• NH
  National Human Genome Research Institute

  Awards: U54 HG003079, HG003079, NHGRI U54 HG003079
• NC
  National Cancer Institute

  Awards: CA101937, PO1 CA101937, U54 HG003079